A Phase 3 interventional study of [18F]Fluorbetazine injection in Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), sponsored by HTA Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by HTA Co., Ltd. · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 309 studies in Cognitive Dysfunction with a site in China — 143 open to participants now, 155 under way, 8 of them phase 3. Cognitive Dysfunction · China.
Among the 309 studies in Cognitive Dysfunction with a site in China, this one is the 21st largest by planned enrollment of the 190 interventional ones that give a count, is one of 32 that started in 2025, is one of 12 in phase 3, reaches primary completion later than 104 of the 154 other live ones, and was the 231st registered.
3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,120 are open to participants now.
Browse Cognitive Dysfunction studies →143 of the 309 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:
Shanghai University of Sport · Sites in China
Ages 60–80
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Sites in China
Ages 35–80
Beijing Tiantan Hospital · Sites in China
Ages 12–70
Shanghai University of Sport · Sites in China
Ages 65+
Risen (Suzhou) Pharma Tech Co., Ltd. · Sites in China
Ages 50–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.
This study: 40 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
309 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 17 · Phase 4 15
First in 2000; this study’s year is marked. 32 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 64 across 2,799 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 110 across the 190 interventional studies, 300 across the 119 observational. Of the 90 that completed or were terminated, 3 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 309 have an industry lead sponsor. The 10 most frequent:
HTA Co., Ltd. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
HTA Co., Ltd. has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
34 of the studies in Cognitive Dysfunction with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07603102Nanjing Mingzhou Rehabilitation HospitalMindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment | 2026-11 |
| NCT06417086ZhanYJClinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers | 2026-11-30 |
| NCT07760415Xiangya Hospital of Central South UniversityEEG Changes and Cognitive Profiles in Sepsis Patients With Different Inflammatory Phenotypes | 2026-12-12 |
| NCT03810794Jian Pei,MDClinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease | 2026-12-30 |
Add all 34 to your calendar (.ics) → With an account.
Among the 309 studies in Cognitive Dysfunction with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multicenter phase III clinical study evaluating the diagnostic performance and safety of PET for the deposition of Aβ plaques in the brain of participants with normal cognitive function, MCI and AD using [18F]Fluorbetazine injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1 1. Men or women aged ≥ 40 years (including the threshold age). 2. Men or women with fertility must use effective measures during the study period. Effective contraceptive measures include sterilization, intrauterine hormone devices, condoms, birth control pills, abstinence, or vasectomy.
3. Meet the diagnostic criteria for normal cognitive function, Mild Cognitive Impairment (MCI), or Alzheimer's disease (AD).
4. Participants voluntarily join the study, can cooperate with the experimental observations, and sign a written form. For participants with AD dementia, the informed consent form must be signed together with their legal guardian. If the participant is unable to sign the informed consent form due to limited cognitive ability or other reasons, the participant's signature space may be left blank, with the reason documented. The guardian should sign in the designated space for explanation.
Exclusion Criteria:
Cranial MRI scan shows one or more of the following results:
Participants with Normal Cognitive Function
1. Any evidence suggesting the possibility of AD from previous MRI, CT, or other biomarker studies.
MCI and AD Dementia Participants
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: [18F]Fluorbetazine injection
normal cognitive function, mild cognitive impairment (MCI) caused by Alzheimer's disease (AD) using \[18F\]Fluorbetazine injection.
The sensitivity and specificity of PET imaging visual interpretation results compared to true standards after a single intravenous injection of [18F]Fluorbetazine injection in participants with AD induced MCI, AD dementia and normal cognitive.
The sensitivity and specificity of PET imaging visual interpretation results compared to true standards after a single intravenous injection of \[18F\]Fluorbetazine injection in participants with AD induced MCI, AD dementia and normal cognitive.
Time frame: 1 year
1 Calculate and compare the standard uptake value ratio (SUVR) of cortical target areas (lateral temporal lobe, frontal lobe, posterior cingulate gyrus/anterior cingulate cortex, and parietal lobe) relative to the cerebellum between AD derived MCI/AD dem
1 Calculate and compare the standard uptake value ratio (SUVR) of cortical target areas (lateral temporal lobe, frontal lobe, posterior cingulate gyrus/anterior cingulate cortex, and parietal lobe) relative to the cerebellum between AD derived MCI/AD dementia participants and cognitively normal participants, and determine the diagnostic performance of SUVR;
Time frame: 1year
2 Using Kappa coefficient to compare the consistency of visual analysis of PET imaging among independent readers, within readers, and overall
2 Using Kappa coefficient to compare the consistency of visual analysis of PET imaging among independent readers, within readers, and overall
Time frame: 1year
3 Calculate the cerebral gray matter to white matter SUV ratio (GWR) on PET images of AD derived MCI/AD dementia participants and cognitively normal participants, and evaluate image features.
3 Calculate the cerebral gray matter to white matter SUV ratio (GWR) on PET images of AD derived MCI/AD dementia participants and cognitively normal participants, and evaluate image features.
Time frame: 1year
The safety assessment is based on serious adverse events, adverse events
Serious adverse events and adverse events during the research period;
Time frame: From the first day of application to one week after administration
Plan to share: No — Individualized patient data needs to be kept confidential
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.
Of 49 phase 3 interventional studies under Cognitive Dysfunction, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 63. This study's planned 30 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
HTA Co., Ltd.